ZKAB001 + carboplatin + etoposide

ZKAB001 + carboplatin + etoposide is a combination regimen used in oncology clinical trials, specifically for the first-line treatment of extensive-stage small-cell lung cancer (ES-SCLC). ZKAB001 is a fully human monoclonal antibody targeting Programmed Death-Ligand 1 (PD-L1), functioning as an immune checkpoint inhibitor. Carboplatin is a platinum-based chemotherapeutic agent that induces DNA crosslinking and apoptosis, while etoposide is a topoisomerase II inhibitor causing DNA damage and cell death. The combination leverages immune activation through PD-L1 blockade alongside cytotoxic chemotherapy, aiming for superior antitumor synergy and clinical efficacy[7].

Other names

ZKAB001ZKAB-001ZKAB 001